14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ALGN vs RBOT.WS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Align Technology Inc (ALGN) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALGN carries a Unified Composite Score of 40.4/100 (SELL) at $155.17 (12.6x Forward P/E, 19.6% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ALGN 40.4/100 SELL), ALGN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (19.6% vs. N/A operating margin) and revenue trajectory (+1.9% vs. N/A YoY).
Technical & Structure Timing Caution: ALGN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.8); meanwhile RBOT.WS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALGN vs RBOT.WS. Trailing 12-month operating profitability (ALGN 19.6% vs RBOT.WS N/A) and valuation multiples (ALGN 12.6x vs RBOT.WS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ALGN vs RBOT.WS Key Questions & Quantitative Answers
As of Nov 20, 2026, Align Technology Inc (ALGN) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ALGN carries a Unified Composite Score of 40.4/100 (SELL) at $155.17 (12.6x Forward P/E, 19.6% operating margin), whereas RBOT.WS carries 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ALGN 40.4/100 SELL), ALGN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (19.6% vs. N/A operating margin) and revenue trajectory (+1.9% vs. N/A YoY). Technical & Structure Timing Caution: ALGN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.8); meanwhile RBOT.WS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ALGN leads the Growth & Scale pillar: ALGN posts +1.9% YoY revenue growth and +143.6% YoY earnings growth on $4.16B TTM revenue (71.5% gross margin, 19.6% operating margin), compared with RBOT.WS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ALGN generates $4.16B in USD-normalized revenue versus N/A for RBOT.WS. In operating R&D and SG&A reinvestment, ALGN deploys 51.9% of Rev ($2.16B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RBOT.WS.
ALGN screens cheaper on headline valuation multiples. ALGN trades at 12.6x Forward P/E, 23.3x Trailing P/E, 0.75x PEG, and 2.5x EV/Revenue (14.5% FCF margin), whereas RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALGN (11.9% ROE) versus RBOT.WS (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ALGN carries 31.9% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (1.15β · 46% Vol realized risk). By comparison, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.